CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Apatinib plus Camrelizumabdrug
Likely dose
Apatinib plus Camrelizumab 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642664
NCT04642664Phase 2Completed
CompareCT.gov

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC): A Prospective Clinical Study

Peking Union Medical College Hospital·interventional·Posted Nov 24, 2020·Updated Jun 3, 2021

In Brief

A Phase 2 clinical trial evaluating Apatinib plus Camrelizumab for Biliary Tract Cancer and 3 related conditions. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

The investigators design a prospective clinical study to explore the efficacy and safety of apatinib plus camrelizumab in pretreated patients with advanced biliary tract malignant tumors and to analyze potential biomarkers of therapeutic response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer, Cholangiocarcinoma, Biomarker, Hepatobiliary Neoplasm
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 24, 2020
Enrollment StartDec 1, 2018
Primary CompletionDec 1, 2020
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 5.6 years ago

Interventions

Apatinib plus Camrelizumabdrug

Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.